Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth

Business Wire September 9, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 4, 2020

UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel(TM) Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence

Business Wire August 27, 2020

UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

Business Wire August 10, 2020

UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

Business Wire August 3, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 5, 2020

UroGen Pharma to Present at Jefferies Virtual Healthcare Conference

Business Wire June 1, 2020

UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer

Business Wire May 15, 2020

UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto(TM) in Patients with Low-Grade Upper Tract Urothelial Cancer

Business Wire May 15, 2020

UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments

Business Wire May 7, 2020

UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020

Business Wire May 1, 2020

The Lancet Oncology Publishes Details of UroGen Pharma's Pivotal OLYMPUS Trial

Business Wire April 30, 2020

UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto(TM), the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer

Business Wire April 15, 2020

UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Business Wire April 3, 2020

UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development

Business Wire March 23, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 6, 2020

UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments

Business Wire March 2, 2020

UroGen Pharma Announces March 2020 Investor Conference Schedule

Business Wire February 25, 2020

UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020

Business Wire February 24, 2020

UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

Business Wire January 8, 2020